$ZYME has generated 10 mentions from 2 distinct FinTwit voices over the past 12 months, with the first mention appearing on 2025-10-19. Jacob Plieth (@jacobplieth) is the most active voice discussing the biotech company, responsible for 9 of the 10 mentions, while InvestmentGuru (@investmentguru_) contributed 1 mention. The discussion has spanned from October 2025 through June 2026.

Recent conversation from @jacobplieth has focused on $ZYME's pan-RAS inhibitor payload ADCs presented at AACR26, with analysis of the therapeutic approach targeting RAS-mutated tumours expressing specific antigens including PTK7, Ly6E, and Claudin18.2. Additional commentary has touched on deal-related aspects and comparative biotech developments.